Phaseline

Companies › Acurx Pharmaceuticals

Acurx Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ibezapolstat (ACX-362E)
Bacterial DNA topoisomerase inhibitor
–Phase 2Clostridium Difficile Infection RecurrenceSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07513285Ibezapolstat (ACX-362E)Phase 2Clostridium Difficile Infection RecurrenceInfectious diseaseSep 2027

From the company's SEC filings

Cash of $11m on 2026-06-30; operating cash outflow about $6m a year; runway about 20 months at that burn, to Mar 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

60 Degrees Pharmaceuticals Lakewood-Amedex Traws Pharma Amplexd Therapeutics Sano Chemicals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.